AU Patent

AU2018322059C1 — BCL-2 inhibitors

Assigned to Guangzhou Lupeng Pharmaceutical Co Ltd · Expires 2024-09-12 · 2y expired

What this patent protects

The disclosure includes compounds of Formula (A): wherein R

USPTO Abstract

The disclosure includes compounds of Formula (A): wherein R

Drugs covered by this patent

Patent Metadata

Patent number
AU2018322059C1
Jurisdiction
AU
Classification
—
Expires
2024-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Guangzhou Lupeng Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.